Home Biosimilar Antibodies Immunology & Inflammation Immunology & Inflammation related Ipilimumab (anti-CTLA-4)
For research use only. Not for use in humans.

Ipilimumab (anti-CTLA-4)

Synonyms: CTLA4， CD152

Ipilimumab (anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor. MW : 148 kD.

Ipilimumab (anti-CTLA-4) Chemical Structure

Click to purchase the isotype control of Ipilimumab (anti-CTLA-4)

20 Citations

The Nobel Prize

17 Nobel Prize winners have used Selleck products

Shimon Sakaguchi

Nature Communications 2025,16, Article number:1325

David Baker

Dev Cell 2023, 58(20):2163-2180.e9.

David Julius

Cell 2017, 185-198.e16

Michael Houghton

Cell Chem Biol, 2020, 27(7):780-792.e5

Charles M. Rice

Cell 2018, 172(3):423-438.e25

Quality Control

Batch: A200109 Purity: 99% Protein concentration: 8.873mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Ipilimumab (anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor. MW : 148 kD.
Features
Human IgG1
Targets/IC50/Ki
CTLA-4
(Cell-free assay)
In vitro

Pembrolizumab plus ipilimumab and nivolumab plus ipilimumab with chemotherapy have been approved by FDA for the first-line treatment of NSCLC patients.
Cell Research

For the intracellular cytokine analysis of TILs, cells from dissociated tumors in the density range of 1×105 to 1×106 cells were cultured in a 96-well U-bottom plate containing 10 µg/mL of pembrolizumab, 10 µg/mL of ipilimumab, soluble 50 ng/mL of anti-CD3, and 50 ng/mL of anti-CD28 for 24 h at 37°C, followed by the addition of brefeldin A and monensin. To measure interferon (IFN)-γ and tumor necrosis factor (TNF) secretion levels by CD8+ TILs according to PD-1 expression on anti-CD3 and anti-CD28 stimulation, the pre-incubation step without brefeldin A and monensin for 24 h was omitted. After 12 h, the cells were harvested and stained. Intracellular cytokines were stained after surface staining, fixation, and permeabilization with Foxp3 fixation/permeabilization solution.
In vivo

64Cu-labeled ipilimumab may be used to noninvasively monitor CTLA-4-expressing tissues in vivo.
Animal Research

AnimalModels:Female athymic nude mice of human lung adenocarcinoma xenograft model
Formulation:buffer-exchanged to PBS, and conjugated with DOTA for radiolabeling with 64Cu (t1/2 = 12.7 h)
Dosages:~1 mg/mL
Administration:i.v.[2]

 
References

Product Details

CAS No. 477202-00-9
Isotype Human IgG1
Source CHO cells
Sterility 0.2 μM filtered
Formulation PBS buffer, pH 7.2
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07770100 NOT_YET_RECRUITING Drug: Pembrolizumab|Drug: Nivolumab|Drug: Atezolizumab|Drug: Head and Neck Cancer; Non-Small Cell Lung Cancer; Cervical Cancer; Esophageal Cancer; Gastric Cancer (GC) Mark Bernard 2026-10-01 PHASE2
NCT02498756 NOT_YET_RECRUITING Drug: Ipilimumab Melanoma The First People's Hospital of Changzhou 2015-08 PHASE2
NCT07510334 RECRUITING Advanced Clear Cell Renal Cell Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8 Mayo Clinic 2026-04-21 PHASE2
NCT07383441 RECRUITING Drug: Axitinib|Drug: Cabozantinib|Drug: Clostridium butyricu Advanced Clear Cell Renal Cell Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8 SWOG Cancer Research Network 2026-06-05 PHASE3
NCT05112601 RECRUITING Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Dedifferentiated Carcinoma; Endometrial Endometrioid Adenocarcinoma; Endometrial Mixed Cell Adenocarcinoma; Endometrial Mucinous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Endometrioid Adenocarcinoma; Recurrent Endometrial Carcinoma National Cancer Institute (NCI) 2022-06-02 PHASE2
NCT06364631 RECRUITING Drug: Nivolumab|Drug: Ipilimumab|Drug: Pembrolizumab|Drug: C Metastatic Kidney Cancer; Metastatic Kidney Carcinoma Gustave Roussy, Cancer Campus, Grand Paris 2024-04-12 PHASE3

(data from https://clinicaltrials.gov, updated on 2026-08-20)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How to store the antibody?

Answer:
Store the undiluted solution at 4 °C in the dark. Freezing antibodies can result in a loss of activity caused by the freezing/thawing process. Diluting antibodies to working concentrations and storing at 4°C for more than a day should be avoided. Additionally, make sure to keep the antibody sterile. Under these storage conditions, your antibodies should remain active for up to one year and oftentimes longer.